Ubiquitin is a tiny cellular molecule that has a part in regulating some of the most vital functions of the body. And researchers are finding out more and more that, like its name, it’s ubiquitous in many seemingly unrelated illnesses and diseases.
Researchers across many disciplines — infectious disease, inflammation, gastroenterology and chemical physiology — are using this grant funding to see how all of these systems interact with the small protein.
It could be key to gaining a deeper understanding of how a wide range of diseases are developed and can be treated.
Jonathan Pruneda, an associate professor of molecular microbiology and immunology at OHSU, joins us to talk more about the ubiquitin process and this collaboration across research disciplines.
Note: The following transcript was transcribed digitally and validated for accuracy, readability and formatting by an OPB volunteer.
Dave Miller: This is Think Out Loud on OPB. I’m Dave Miller. We start today with ubiquitin. It’s a small protein that plays a big role regulating some of the most vital cellular functions in all animals, plants and fungi. When it goes wrong, it’s been implicated in all kinds of ailments from infectious disease and inflammation to cancer and stroke. A multidisciplinary team of researchers at OHSU have received more than $12 million from the National Institutes of Health and private foundations to learn more about ubiquitin. I’m joined now by one of those scientists. Jonathan Pruneda is an associate professor of molecular microbiology and immunology at OHSU. It’s great to have you on the show.
Jonathan Pruneda: Thank you so much for having me.
Miller: How do you describe ubiquitin?
Pruneda: We think about ubiquitin as a signal inside cells. And so, one way you can conceptualize it, it’s like a traffic signal on your way to work. If everything’s going smoothly, traffic is flowing, we don’t often think about it. You get from point A to point B. But if there’s a traffic signal that’s out or an accident, you can have these traffic jams, and it’s just like that in the cell. Inside cells, every protein needs to be told what to do, where to go, whether to be recycled, and ubiquitin is in charge of that.
Miller: I tried to understand a little bit of the pathways of how this works yesterday and today, and very quickly I got very confused, but one thing I think I learned is that it actually gets attached to cells and changing what happens, or attached to other proteins and changing the way they behave – giving the message, “Hey,” to other things floating around in the cell, “destroy this thing.” You said recycle it, which is maybe a more polite way to put it, or change behavior. So what are the various things that ubiquitin can do within a cell?
Pruneda: The classical role is to tell this protein to be degraded or recycled.
Miller: Because sometimes something that’s been identified as not being good for the cell anymore.
Pruneda: Right. Maybe it gets too old and it’s damaged and needs to be recycled and have a new protein built in its place. Maybe it’s just part of a signaling response that we have this protein around until we want to rapidly change our direction, change how we respond to an infection, for example. And so it’s part of that process as well as being able to quickly pivot the way our cells respond to different environmental cues.
Miller: One thing I’ve read is that an important feature of ubiquitin signaling is that it’s reversible. Why is that important?
Pruneda: Again, part of that ability to rapidly respond to cues. Sometimes we want to have it on versus off, and this is a much, much faster way to respond to something than going back to the DNA and having to create new protein. So by having on-off switches like ubiquitin, we’re able to very quickly change our behavior.
Miller: Why is it called ubiquitin?
Pruneda: It’s because it’s ubiquitous. It’s very on point, so ubiquitously made in all cells throughout our body, and plays different roles in those contexts. And now over time we’ve begun to appreciate that it’s also ubiquitously utilized across different signaling processes so it’s very aptly named.
Miller: How did you become interested in this?
Pruneda: For me it was really just how modular the system is and appreciating more and more about how complex it is. If we were to go back to that traffic analogy, back in the ‘80s, it was originally discovered and thought to be a one-lane highway, and now it’s really like the downtown New York traffic system. It’s really complex. The more we study it, the more we learn how amazing it is and how broadly it’s utilized across biology.
Miller: So, it’s not just your team, this has become a more popular field of study around the world.
Pruneda: Across the world, yeah, this research has been going on for almost 50 years, and we’ve been part of it for almost 20.
Miller: What can go wrong, then, when the ubiquitin pathway gets messed up?
Pruneda: Sometimes you can think about that with a mutation and the enzymes that are used to regulate ubiquitin signals. It’s not being turned on and off properly or it’s not imparting the right signal anymore. And part of it is that you’re thinking about external cues or manipulation, so where we study it actually is mostly in the context of bacterial infection. Bacteria themselves don’t have ubiquitin, but they actually target it during infection to rewire those responses during invasion of the host cell.
Miller: As part of their attack, they make it so it’s harder for ubiquitin to perform its regular way?
Pruneda: Yeah.
Miller: Why might that be beneficial for a bacteria?
Pruneda: The ubiquitin signal is also an integral part of the immune response. It’s our ability to respond to an infection and mount this defense. And bacteria figured out that by rewiring that, turning it off, they’re able to survive inside cells.
Miller: OK, so that is infectious disease. What about something like cancer?
Pruneda: That’s often where we need to know, as part of our quality control of cellular division, let’s say, we want to multiply cells. Ubiquitin is an important part of that checkpoint to say, is this cell healthy or is it not? Because if it’s not healthy, we should just stop and let that cell die off. And if that process isn’t tightly controlled by ubiquitin, then it can go out of whack, and you can have multiple cell divisions and that leads to cancer.
Miller: Parkinson’s is another disease that was mentioned in the press release for your research. What’s the connection between a neurodegenerative disease like that and ubiquitin?
Pruneda: It’s similar. It’s a quality control issue. Ubiquitin is in charge of a lot of the quality control happening inside our cells. And in that case, it’s quality control of a particular part of the cell called the mitochondria. If you can’t control that properly, it goes out of whack and can lead to these neurodegenerative diseases.
Miller: Can you describe then, in layman’s terms, the big questions that you and your team have now? Because so far, you’ve laid out just how pervasive this is, and how many things can go wrong. What are the big questions that you’re interested in getting answers to?
Pruneda: What’s really exciting about the research that’s been funded over the past years, it really ranges from the very fundamentals of ubiquitin signals. For example, our work with Dr. Michael Cohen is trying to understand how ubiquitin is fused together with another signaling process that he has studied for decades. And actually, we find that they work together and it creates a new type of signal, but also, it ranges all the way into more physiologically relevant work with our work with Dr. Isabella Rauch and Tim Nice, where we’re studying the role of this during a bacterial infection, but also in the context of IBD where some of those same pathways are not functioning properly, but in that case outside…
Miller: Something like Crohn’s disease?
Pruneda: Exactly, right. Some of the same ubiquitin regulation is not functioning properly, but whether it’s being pushed out of proper function by the bacteria or some sort of genetic cause, that’s what we’re trying to figure out. What are the relationships there.
Miller: Can you give us a sense for the different disciplines of the people that you’re working with, the people you just outlined, because it seems like one of the interesting pieces of this research is the variety of the disciplines you all come from.
Pruneda: That’s the power of, I think, collaboration, especially at OHSU, where we’re trying to bring together different disciplines to tackle one central question. I myself have used more of a biochemistry and structural biology methodology, which involves reconstituting, simplifying these systems and trying to be able to get them to work in a simple system like a test tube. I’ve worked with Dr. Michael Cohen, who has more of a biochemistry chemical biology perspective of building tools, designing new drugs, translating that work into therapies, and also Dr. Isabella Rauch adds a background in bacterial infection and the immune response to that and using complicated models of what we call organoids or mini guts, and that also connects to Dr. Tim Nice’s expertise in mini guts, but in that case, more the connection to IBD. So what’s happening outside of infection that is a similar, misregulated immune response.
Miller: What is a mini gut, or what are mini guts?
Pruneda: It’s our attempt to try and recreate an intestine inside of a petri dish, and that way we can study this complicated system in a more controlled setting so that we can ask very specific questions.
Miller: How far away are you or other researchers from turning the various versions of basic science – or science is maybe more further along than that – but into therapeutics?
Pruneda: This is already ongoing, and not necessarily in our hands. You know, it takes decades of fundamental research to lead to a new therapy. But our work to understand how bacteria, for example, rewire this ubiquitin process is essentially what biotech companies are trying to do now, but with therapies. So, there’s actually just this year, the first FDA approved therapy that is rewiring the ubiquitin system for our own kind of medicinal purpose.
Miller: Jonathan Pruneda, thanks very much.
Pruneda: Thanks for having me. This was fun.
Miller: Jonathan Pruneda is an associate professor of molecular microbiology and immunology at OHSU.
“Think Out Loud®” broadcasts live at noon every day and rebroadcasts at 8 p.m.
If you’d like to comment on any of the topics in this show or suggest a topic of your own, please get in touch with us on Facebook, send an email to thinkoutloud@opb.org, or you can leave a voicemail for us at 503-293-1983.
